CARLSBAD, Calif. and BOSTON, Aug. 8, 2019 /PRNewswire/ — The second annual Selections from DISORDER: The Rare Disease Film Festival at Biotech Week Boston will be held at the Takeda Auditorium in Cambridge, MA, on September 12 from… […]
SAN DIEGO, Aug. 8, 2019 /PRNewswire/ — Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today … […]
— Preliminary Phase 2 results for hepcidin mimetic PTG-300 in beta-thalassemia are expected in the fourth quarter of 2019 —- Phase 2 study of PTG-300 in polycythemia vera expected to begin in the third quarter of 2019; studies in hereditary hemochro… […]
– Total Revenues Increase 11% to $39.1 Million Compared to $35.2 Million in Prior-year Period — ENHANZE® Partner Janssen Submits Regulatory Applications for Subcutaneous Formulation of DARZALEX® in the U.S. and EU — Pivotal Phase 3 Trial Results from… […]
SAN DIEGO, Aug. 5, 2019 /PRNewswire/ — Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the second quarter ended June 30, 2019.
Second Quarter Highlights:
Initiated the Phase… […]
Amphora NDA Resubmission Remains on Track for Q4 2019Management to Host Conference Call Tuesday August 6, 2019 at 11:00 a.m. EDT
SAN DIEGO, Aug. 5, 2019 /PRNewswire/ — Evofem Biosciences, Inc., (NASDAQ: EVFM) (“Evofem” or the “Company”), a clinical … […]
SAN DIEGO, Aug. 5, 2019 /PRNewswire/ — Evofem Biosciences, Inc. (NASDAQ: EVFM) (Evofem), a clinical-stage biopharmaceutical company, today reported additional data from its Phase 3 ‘AMPOWER’ clinical trial of Amphora® for the prevention of pregnanc… […]
– Featured health networks improve patient care through innovative technologies and optimizing operations- Digital tools harness rich data streams to provide clinical decision support, patient insights and improved operational effectiveness
INDIANAPO… […]
SAN DIEGO, Aug. 1, 2019 /PRNewswire/ — Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced it will report its second quarter 2019 financial results and business progress on Thursday, August 8, 2019,… […]
Conference call scheduled for 4:30 p.m. ET today- Preparation for Phase 2b Study of VK2809 in Biopsy-Confirmed NASH Underway; Expect to Commence Enrollment in 2H19- Continued Progress with VK0214 for X-ALD; Expect to Commence Phase 1 Clinical Study in … […]
Copyright © 2019 San Diego Biotechnology Network (DBA of Comprendia. LLC)
